Hugel Achieves Impressive Financial Milestones in 2024
Hugel Inc. has reported remarkable financial performance for the year 2024, showcasing a significant increase in both net sales and profits. The company recorded net sales of KRW373.0 billion, which reflects a year-over-year growth of 16.7%. Additionally, Hugel's operating profit surged to KRW166.3 billion, marking a 41.2% increase, while its net income soared by 45.8% to KRW142.4 billion.
Outstanding Fourth Quarter Performance
In the fourth quarter of the year alone, Hugel achieved net sales of KRW98.2 billion. This represents a year-over-year growth of 10.4%. Operating profit during this period was KRW46.6 billion, showing a remarkable increase of 26.7%. Furthermore, the company noted a significant surge in net income of 130%, reaching KRW40.7 billion for the fourth quarter.
Growth Driven by Toxin and Fillers
The substantial growth in Hugel's net sales can primarily be attributed to its flagship products: botulinum toxin, hyaluronic acid (HA) fillers, and cosmetics. In 2024, sales from the botulinum toxin, known as Botulax domestically and Letybo internationally, reached KRW203.2 billion, reflecting a 20.2% increase from the previous year. The overseas sales of this product experienced a remarkable 39.6% growth, primarily due to strong market performance in key Asia-Pacific regions, including shipments to the US and Europe.
Solid Performance of Hyaluronic Acid Fillers
Hugel’s HA fillers, branded as THE CHAEUM and BYRYZN in South Korea and globally recognized as Revolax, saw substantial revenue as well. The net sales reached KRW127.6 billion, bolstered by a 13.2% rise in international sales, with notable growth across China, Europe, the Middle East, and North Africa (MENA). This emphasizes Hugel's commitment to enhancing marketing strategies and maintaining its leadership position both locally and globally.
Dynamic Cosmetics Sector Growth
Furthermore, Hugel's cosmetics line experienced incredible growth, with net sales increasing by 37.8% to KRW36.9 billion in 2024. Notably, in the fourth quarter, the cosmetics sector's sales surged by 48.1% year-over-year to KRW11.7 billion. Hugel is enhancing its brand value through the introduction of innovative products, such as the Hyper Peptide series introduced in August and BYRYZN BR, launched in early 2024.
Global Expansion Strategies
Looking ahead, Hugel plans to significantly enhance its international presence. The company's focus will be on marketing initiatives in the US, where it aims to launch its botulinum toxin within the year. Hugel is ambitious, targeting to capture a 10% share of the US medical aesthetics market over the next three years through strategic pricing and educational events for medical professionals.
Expanding Presence in MENA Markets
Expansion efforts are also directed towards MENA markets, where Hugel is seeking a robust presence. The company has set its sights on achieving a 30% market share in these developing markets within a three-year timeline. Key countries like the United Arab Emirates and Kuwait are pivotal to this strategy, especially after receiving the marketing license in the UAE earlier this year.
Commitment to Industry Leadership
An official from Hugel stated, "Our achievements in 2024 reflect our strong growth in botulinum toxin, HA fillers, and the cosmetics segment. We will continue to foster our leadership in Asia-Pacific and Europe while pursuing additional market expansions in North America and MENA.” Hugel's proactive approach emphasizes its commitment to growth and sustaining its industry-leading position.
About Hugel
Founded in 2001, Hugel has established itself as a leader in the medical aesthetics field, dedicated to producing innovative injectables for skin rejuvenation, including botulinum toxin and hyaluronic acid fillers. As a frontrunner in South Korea's aesthetics landscape, Hugel is unique in holding regulatory approvals in the largest global markets, including the US, China, and Europe. The company focuses on ensuring safety and quality while enhancing the industry through comprehensive training and medical engagements. With a footprint in around 70 countries and numerous global subsidiaries, Hugel is poised for substantial growth and expansion in the medical aesthetics market.
Frequently Asked Questions
What financial milestones did Hugel achieve in 2024?
In 2024, Hugel reached net sales of KRW373.0 billion, operating profit of KRW166.3 billion, and net income of KRW142.4 billion, marking substantial year-over-year increases.
How did the cosmetics segment perform?
The cosmetics segment experienced significant growth, with net sales up 37.8% year-over-year to KRW36.9 billion, and a remarkable 48.1% increase in the fourth quarter sales.
What is Hugel's expansion plan for the US market?
Hugel plans to officially launch its botulinum toxin in the US within the year, aiming for a 10% share of the medical aesthetics market within three years.
What are the key markets for Hugel's growth?
Hugel's key growth markets include the US and MENA regions, where the company aims to secure substantial market presence and shares in the coming years.
What products drive Hugel's financial success?
Hugel’s financial success is primarily driven by its botulinum toxin, hyaluronic acid fillers, and the rapidly growing cosmetics product line.
